Edwin R. Parra - Concepedia

Author

Edwin R. Parra

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

E PARRA, E Parra, E R Parra, E. Parra, E.R. Parra, E.R. Parra Cuentas, Edwin Parra, Edwin R Parra, Edwin R. Parra, Edwin R. Parra Cuentas

650

Publications

15K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Baylor College of Medicine NYU Langone Health Dana-Farber Cancer Institute Massachusetts General Hospital

About

Edwin R. Parra is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	38	4.1K
2	Cell Biology	9	9	505
3	Engineering	2	2	86
4	Health Sciences	1	1	73
5	Biomedical Engineering	1	1	37

Edwin R. Parra

112

Publications

13.6K

Citations

H-Index

Page 1

	Year	Citations
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Cancer Discovery	2018	1.5K
Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Ferdinandos Skoulidis, Lauren A. Byers, Lixia Diao, Cancer Discovery	2015	883
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial Mariano Provencio, Ernest Nadal, Amelia Insa, The Lancet Oncology MedicineImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation Oncology	2020	788
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis Yinghong Wang, Diana H. Wiesnoski, Beth A. Helmink, Nature Medicine DysbiosisIntestinal TransplantationMucosal ImmunologyImmunologyUlcerative Colitis	2018	692
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial Tina Cascone, William N. William, Annikka Weissferdt, Nature Medicine Neostar TrialMedicineImmune Checkpoint InhibitorCancer TreatmentPhase 2	2021	582
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition Milena Perez Mak, Pan Tong, Lixia Diao, Clinical Cancer Research	2015	560
Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma Yanyan Lou, Lixia Diao, Edwin R. Parra, Clinical Cancer Research	2016	437
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion David H. Peng, B. Leticia Rodriguez, Lixia Diao, Nature Communications	2020	420
A proteogenomic portrait of lung squamous cell carcinoma Shankha Satpathy, Karsten Krug, Pierre M. Jean Beltran, Cell	2021	365
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation Janis M. Taube, Güray Aktürk, Michael Angelo, Journal for ImmunoTherapy of Cancer	2020	275

Page 1